Evidence map›Paper›PMID 37396505›Full record

ArticleGenes & diseases2023

A novel aptamer-based small RNA delivery platform and its application to cancer therapy.

Toshihiko Tanno, Peng Zhang, Christopher Bailey, Yin Wang, Wannaporn Ittiprasert, Martin Devenport, Pan Zheng, Yang Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes & diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Toshihiko TannoOncoC4, Inc., Rockville, MD 20850, USA.
Peng ZhangDivision of Immunotherapy, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Christopher BaileyDivision of Immunotherapy, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Yin WangDivision of Immunotherapy, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Wannaporn IttiprasertDepartment of Microbiology, Immunology and Tropical Medicine, School of Medicine and Hygiene, George Washington University, NW Washington, DC 20037, USA.
Martin DevenportOncoC4, Inc., Rockville, MD 20850, USA.
Pan ZhengOncoC4, Inc., Rockville, MD 20850, USA.
Yang LiuOncoC4, Inc., Rockville, MD 20850, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Major challenges such as nuclease degradation, rapid renal clearance, non-specific delivery, poor cellular uptake and inflammatory response have limited the clinical application of small RNA-mediated gene silencing. To overcome these challenges, we designed a novel targeting small RNA delivery platform comprising of three oligonucleotides: (1) a guide RNA sequence, (2) part of a passenger sequence linked to a DNA aptamer via a PEG linker, and (3) another passenger sequence conjugated to cholesterol, which assemble through complementary base pair annealing. Remarkably, in the presence of magnesium, this molecule self-assembled into a nanoparticle with a hydrophobic cholesterol core, hydrophilic RNA oligonucleotide shell and PEG-linked DNA aptamer flare. The nanoparticles conferred protection to the RNA oligonucleotides against nuclease degradation, which increased bioavailability, and reduced systemic inflammatory responses

Indexed as

AptamerCancerMicellar nanoparticlemiRNATarget delivery

Identifiers

PMID37396505
PMCPMC10308127

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.